Kliniske studier for Gliom i Massachusetts
20 studier for Gliom søker deltakere på steder i Massachusetts.
Byer i Massachusetts
Offisiell studietekst (engelsk)
MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Rekrutterer
Alle aldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06000787A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
12 Months – 21 Years · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07326566A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
RekruttererFase 1/2
Opp til 25 år · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04094610Targeted Pediatric High-Grade Glioma Therapy
- Dana-Farber Cancer Institute, Boston
RekruttererObservasjonsstudie
12 Months – 39 Years · Alle kjønn · Oppdatert 8. sep. 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
RekruttererFase 2
Alder 12 til 39 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 3 til 39 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05096481Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
RekruttererFase 1/2
Alder 18 til 130 · Alle kjønn · Oppdatert 12. aug. 2026 · NCT05417594A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797CARv3-TEAM-E T Cells in Glioblastoma
- Massachusetts General Hospital Cancer Center, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 14. jul. 2026 · NCT05660369Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Dana-Farber Cancer Institute, Boston
RekruttererTidlig fase 1Frivillige helsepersonell ønskes velkommen
Alder 1 til 21 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
12 Months – 39 Years · Alle kjønn · Oppdatert 29. mai 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. apr. 2026 · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Dana-Farber Cancer Institute, Boston
RekruttererTidlig fase 1
Opp til 21 år · Alle kjønn · Oppdatert 18. mar. 2026 · NCT04655404rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
RekruttererFase 1
12 Months – 18 Years · Alle kjønn · Oppdatert 17. mar. 2026 · NCT04943848CUE-102 in Recurrent Glioblastoma
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mar. 2026 · NCT06917885NeuroPathways Intervention for Brain Tumor Patients
- Massachusetts General Hospital Cancer Center, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 17. des. 2025 · NCT05976490ASCENT Intervention for Brain Tumor Patients
- Massachusetts General Hospital Cancer Center, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 14. jul. 2025 · NCT06099743The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Massachusetts General Hospital, Boston
RekruttererObservasjonsstudie
Alder 18 til 90 · Alle kjønn · Oppdatert 22. feb. 2024 · NCT06118723Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.